Epidermal growth factor upregulates the expression of A20 in hepatic cells via the MEK1/MSK1/p-p65 (Ser276) signaling pathway.
Haiyang Chen(Henan Cancer Hospital), Qiming Wang(Hunan Cancer Hospital), Xuan Wu(Zhengzhou University), Hongle Li(Shanghai Jiao Tong University), Zhen He(Henan Cancer Hospital), Hanqiong Zhou(Zhengzhou University)
PubMed
January 1, 2021
Cited by 4
Related Papers
Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial
|The Lancet Respiratory Medicine|2020|508
Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
|The Lancet Oncology|2022|417
Camrelizumab Plus Carboplatin and Paclitaxel as First-Line Treatment for Advanced Squamous NSCLC (CameL-Sq): A Phase 3 Trial
|Journal of Thoracic Oncology|2021|311
MEK inhibitors for the treatment of non-small cell lung cancer
|Journal of Hematology & Oncology|2021|300
Radiotherapy remodels the tumor microenvironment for enhancing immunotherapeutic sensitivity
|Cell Death and Disease|2023|130